Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Dicembre 2023 - 2:30PM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that Joseph Payne, President & Chief
Executive Officer, will present at the 42nd Annual J.P. Morgan
Healthcare Conference in San Francisco, on Tuesday, January 9,
2024, at 3:00 p.m. Pacific Time.
A webcast and replay of the presentation will be available on
the “Investor Relations/Events” section of the Company’s website
at: https://ir.arcturusrx.com/investor-calendar.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA
Technology (sa-mRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus developed Kostaive™, the
first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the
world to be approved. Arcturus has an ongoing global collaboration
for innovative mRNA vaccines with CSL Seqirus, and a joint venture
in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and
therapeutics. Arcturus’ pipeline includes RNA therapeutic
candidates to potentially treat ornithine transcarbamylase
deficiency and cystic fibrosis, along with its partnered mRNA
vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, circular RNA, antisense RNA, self-amplifying RNA,
DNA, and gene editing therapeutics. Arcturus’ technologies are
covered by its extensive patent portfolio (patents and patent
applications issued in the U.S., Europe, Japan, China, and other
countries). For more information, visit www.ArcturusRx.com. In
addition, please connect with us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231204612304/en/
IR and Media Contacts Arcturus Therapeutics Neda
Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682
IR@ArcturusRx.com
Grafico Azioni Arcturus Therapeutics (NASDAQ:ARCT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Arcturus Therapeutics (NASDAQ:ARCT)
Storico
Da Giu 2023 a Giu 2024